Do oral semaglutides work for weight loss — and how well?

Step 1: understanding what you're actually taking

Semaglutide is a GLP-1 receptor agonist, it mimics the gut hormone that signals fullness, slows gastric emptying, and dials down appetite. For years it was only deliverable by injection, because the molecule breaks down quickly in the stomach. Novo Nordisk's solution was to co-formulate semaglutide with an absorption enhancer called SNAC, which temporarily raises the local pH around the tablet to protect the drug long enough for it to cross the stomach lining.

The result is the Wegovy tablet: once daily, taken the moment you wake up, before coffee or breakfast. You swallow it whole with no more than about 120ml of plain water, then wait a minimum of 30 minutes before eating, drinking anything else, or taking other oral medicines. It is not interchangeable with the injection; the dosing schedule is its own, 1.5mg to start, then 4mg, then 9mg, reaching the 25mg maintenance dose with at least a month at each level. If you've already been established on the 2.4mg weekly injection, a prescriber may move you directly to the 25mg tablet, though that switch still requires clinical review.

One practical upside worth noting: no refrigeration. The tablets store at room temperature, which makes travel considerably simpler than managing a pen that needs a cool bag. You can read more on our oral Wegovy overview page if you want the fuller picture on how this compares to the injection format.

Step 2: reading the trial results honestly

The headline figure from OASIS 4 is 13.6% average weight loss over 64 weeks, but context matters. That number comes from an intention-to-treat analysis: it includes everyone who received at least one dose, whether or not they completed the trial. Among participants who adhered fully, the average rose to around 17%. Both figures should be in front of you when you decide what to expect.

The trial enrolled 307 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. Participants also followed a reduced-calorie diet and increased their activity levels. Most of the side effects were gastrointestinal (nausea, diarrhoea, constipation) affecting around 74% of those on oral semaglutide versus 42% on placebo. They were generally mild to moderate and tended to ease as the body adjusted, particularly at lower doses in the titration schedule.

The MHRA approved Wegovy tablets based on this evidence, which you can explore via the MHRA's published regulatory communications. What the trial doesn't tell you is how the tablet will perform for any specific individual, that is exactly what a prescriber's assessment is for. Our semaglutide tablets and weight loss page goes deeper on the evidence side if you want to compare figures across different formulations.

Step 3: checking whether the tablet fits your situation

The MHRA licence covers adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition, such as high blood pressure, prediabetes, high cholesterol, or obstructive sleep apnoea. UK guidance also recognises that lower thresholds can apply for some ethnic backgrounds, so a 2.5 kg/m² reduction to those figures may be appropriate depending on your background; a prescriber will factor this in.

The tablet is not suitable for everyone. People who are pregnant, breastfeeding, or trying to conceive are advised against it; the same applies to anyone under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma or a rare condition called MEN2) make GLP-1 medicines unsuitable. There are also practical considerations: the strict morning-routine requirement (empty stomach, no food or other medication for 30 minutes) is easy to underestimate. For people who take other oral medicines early in the day, timing needs careful prescriber discussion. If you're weighing up whether oral semaglutides work well enough to justify that routine, it's worth reading the evidence before you commit. Oral semaglutide drops are a separate and unlicensed topic, the Wegovy tablet is the only oral semaglutide with UK marketing authorisation for weight management.

One more important note on cost: the Wegovy tablet is not yet available on the NHS. NICE has not yet appraised it, so a private prescription is the only legal route at the moment. Our guide to getting the Wegovy tablet in the UK covers where that fits into the private prescription landscape, including what to look for in a legitimate pharmacy. The NICE appraisal for the injectable semaglutide (TA875) may inform the timeline, but no date is confirmed for the tablet review.

Step 4: getting a proper clinical assessment

A prescriber's job here is not just ticking BMI boxes. They'll look at your medical history, current medicines (especially other oral treatments taken in the morning), any contraindications, and whether the daily routine is actually workable for you. If you've been on the injection and want to switch, they'll check you're on the right dose to transition safely.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally, the same day you submit it, not at the end of a queue. There's no algorithm making that call. If treatment is clinically suitable and approved, your order is dispatched the same day for free next-working-day DPD delivery; you'll get a tracking notification on your phone and the package arrives in plain, unbranded packaging. Our pharmacy is registered with the GPhC (registration number 9012878, verifiable at the GPhC register) and medicines come through the licensed UK supply chain. If you'd like to understand our clinical approach before deciding, our clinical team page gives you the background. When you're ready, speaking to our prescribers is the natural next step.